Origins of Deadliest Breast Cancer Identified at Duke
News Nov 01, 2005
Scientists have discovered that loss of a critical protein in breast cells can initiate a particularly aggressive and often fatal form of cancer called "basal type" breast cancer.
They said their discovery is important for identifying women at increased risk for basal-type breast cancer and for developing new drugs that more effectively target this treatment-resistant cancer.
Early detection is particularly important because the disease strikes young women of child-bearing age and typically resists chemotherapy and other front-line drugs, said the researchers from the Duke Comprehensive Cancer Center.
The Duke scientists found that basal-type breast cells which lose expression of the CREB-binding protein (CBP) are unable to engage in programmed cell death or "apoptosis," so the cells over-proliferate. Apoptosis is a critical defense mechanism that cells use to commit suicide when they become irreparably damaged or are no longer needed by the body.
Results of the study are published in the Nov. 1, 2005, issue of the Journal of "Cell Science".
"There hasn't been a good model of basal-type breast cancer, so we haven't understood how this type of cancer starts and thus how to prevent or eradicate it," said Victoria Seewaldt, M.D., director of the Breast Health Clinic at Duke and senior author of the study.
"Our discovery provides a critical clue as to how basal-type breast cancer might start, and this knowledge gives us the power to detect early changes that lead to this type of breast cancer."
Researchers at University of North Carolina at Chapel Hill first identified basal-type breast cancer in 2003 based on its unique pattern of gene expression. Its signature traits include the expression of a protein called cytokeratin 5/6, the loss or mutation of the p53 gene, and the frequent absence of estrogen or progesterone receptors and the Her2/neu protein.
Treatments aimed at suppressing these elements are ineffective against most basal type cancer cells because they generally don't produce those elements, said Seewaldt. In fact, basal-type carcinoma defies all the usual principles of breast cancer onset, said Seewalt.
To characterize the disease, Seewaldt's team analyzed basal-type breast cells from both young African-American and Caucasian women. They studied specific signaling pathways the body uses to eliminate cells that develop a mutation or loss of P53, a tumor suppressor gene.
Cells that lack a functioning P53 gene, then subsequently lose CBP or its downstream target -- the laminin 5 protein -- can no longer undergo apoptosis, said Seewaldt.
Although losing CBP does not guarantee cancer, cells that have also lost CBP protein appear to have lost their ability to eliminate themselves once they become damaged, said Seewaldt.
Moreover, CBP is thought to be important for allowing another breast cancer gene, BRCA1, to repair DNA. Thus, loss of CBP in a woman who has a mutation in the BRCA1 gene may put her at extremely high risk for developing breast cancer, said Seewaldt.
"If we find atypical breast cells in a woman, meaning they are abnormal but not cancerous, and then we find loss of CBP, we would hypothesize that this woman is at very high risk for developing breast cancer in the future," said Seewaldt.
"We think that loss of CBP in women who carry the BRCA-1 mutation may be especially important for helping us predict future risk."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019